Saudi Chemical Holding Company (TADAWUL:2230)
Saudi Arabia · Delayed Price · Currency is SAR 7.05
-0.12 (-1.67%)
Aug 13, 2025, 3:18 PM AST
Ligand Pharmaceuticals Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 6,525 | 6,375 | 4,855 | 3,696 | 3,411 | 3,306 | Upgrade | |
Revenue Growth (YoY) | 11.17% | 31.32% | 31.36% | 8.35% | 3.17% | 12.11% | Upgrade |
Cost of Revenue | 5,622 | 5,501 | 4,183 | 3,209 | 2,980 | 2,870 | Upgrade |
Gross Profit | 902.23 | 874.64 | 671.5 | 486.49 | 431.1 | 435.84 | Upgrade |
Selling, General & Admin | 351.14 | 334.83 | 292.54 | 262.07 | 261.06 | 253.67 | Upgrade |
Operating Expenses | 474.15 | 440.49 | 356.39 | 310.36 | 289.51 | 266.96 | Upgrade |
Operating Income | 428.08 | 434.15 | 315.11 | 176.13 | 141.59 | 168.88 | Upgrade |
Interest Expense | -96.76 | -93.72 | -92.33 | -57.15 | -39.95 | -40.32 | Upgrade |
Interest & Investment Income | 2.31 | 2.31 | 0.11 | 0.41 | - | - | Upgrade |
Earnings From Equity Investments | -7.66 | -7.66 | 3.87 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.34 | -0.79 | -5.15 | -12.45 | -0.55 | - | Upgrade |
Other Non Operating Income (Expenses) | -2.74 | 1.19 | -4.64 | 7.43 | 3.16 | 0.33 | Upgrade |
EBT Excluding Unusual Items | 322.89 | 335.49 | 216.97 | 114.36 | 104.25 | 128.88 | Upgrade |
Gain (Loss) on Sale of Assets | -0.06 | -0.06 | 0.83 | -0.2 | - | - | Upgrade |
Legal Settlements | - | - | - | - | -1.08 | -20.64 | Upgrade |
Other Unusual Items | - | - | - | - | 3.67 | - | Upgrade |
Pretax Income | 322.83 | 335.43 | 217.8 | 114.17 | 106.84 | 108.25 | Upgrade |
Income Tax Expense | 41.41 | 41.41 | 33.67 | 33.18 | 36.37 | 33.2 | Upgrade |
Earnings From Continuing Operations | 281.42 | 294.02 | 184.13 | 80.99 | 70.46 | 75.05 | Upgrade |
Minority Interest in Earnings | -2.6 | -2.78 | -1.25 | -0.76 | -0.89 | -1.02 | Upgrade |
Net Income | 278.82 | 291.24 | 182.89 | 80.22 | 69.57 | 74.03 | Upgrade |
Net Income to Common | 278.82 | 291.24 | 182.89 | 80.22 | 69.57 | 74.03 | Upgrade |
Net Income Growth | -3.28% | 59.25% | 127.97% | 15.31% | -6.02% | 125.16% | Upgrade |
Shares Outstanding (Basic) | 843 | 843 | 843 | 843 | 843 | 843 | Upgrade |
Shares Outstanding (Diluted) | 843 | 843 | 843 | 843 | 843 | 843 | Upgrade |
EPS (Basic) | 0.33 | 0.35 | 0.22 | 0.10 | 0.08 | 0.09 | Upgrade |
EPS (Diluted) | 0.33 | 0.35 | 0.22 | 0.10 | 0.08 | 0.09 | Upgrade |
EPS Growth | -3.28% | 59.25% | 127.97% | 15.31% | -6.02% | 125.16% | Upgrade |
Free Cash Flow | -320.79 | -285.49 | 361.47 | 587.34 | -177.16 | -228.67 | Upgrade |
Free Cash Flow Per Share | -0.38 | -0.34 | 0.43 | 0.70 | -0.21 | -0.27 | Upgrade |
Dividend Per Share | 0.050 | 0.050 | 0.050 | 0.050 | 0.050 | 0.050 | Upgrade |
Gross Margin | 13.83% | 13.72% | 13.83% | 13.16% | 12.64% | 13.18% | Upgrade |
Operating Margin | 6.56% | 6.81% | 6.49% | 4.77% | 4.15% | 5.11% | Upgrade |
Profit Margin | 4.27% | 4.57% | 3.77% | 2.17% | 2.04% | 2.24% | Upgrade |
Free Cash Flow Margin | -4.92% | -4.48% | 7.45% | 15.89% | -5.19% | -6.92% | Upgrade |
EBITDA | 481.84 | 483.62 | 356.73 | 216.86 | 184.1 | 212.14 | Upgrade |
EBITDA Margin | 7.38% | 7.59% | 7.35% | 5.87% | 5.40% | 6.42% | Upgrade |
D&A For EBITDA | 53.76 | 49.47 | 41.62 | 40.73 | 42.51 | 43.26 | Upgrade |
EBIT | 428.08 | 434.15 | 315.11 | 176.13 | 141.59 | 168.88 | Upgrade |
EBIT Margin | 6.56% | 6.81% | 6.49% | 4.77% | 4.15% | 5.11% | Upgrade |
Effective Tax Rate | 12.83% | 12.35% | 15.46% | 29.06% | 34.05% | 30.67% | Upgrade |
Advertising Expenses | - | 4.05 | 2.88 | 2.49 | 1.54 | 0.9 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.